TABLE 10

Intravenous alternatives for the treatment of chronic pulmonary aspergillosis (CPA)

PopulationIntentionInterventionSoRQoERef.
CPA patients with progressiveControl of infectionMicafungin 150 mg·day−1BII[16, 90,
 disease, who fail, are intolerant97–100]
 of or have triazole resistanceAmphotericin B deoxycholate 0.7–1.0 mg·kg−1·day−1CIII[10]
Liposomal AmB 3 mg·kg−1·day−1BIIa[101]
Caspofungin 50–70 mg·day−1CIIa[96, 102]

  • SoR: strength of recommendation; QoE: quality of evidence.